Parkinson's Disease Market is segmented By Type (Juvenile Parkinson Disease, Young-Onset Parkinson’s Disease, Idiopathic Parkinson Disease), By Age (Adult, Pediatric), By Diagnosis(CT Scan, MRI Scan, DaTSCAN-SPECT scan, PET Scan), By Drug Class (Carbidopa-Levodopa, Carbidopa-Levodopa Infusion, Dopamine Agonists, Monoamine Oxidase B Inhibitors, Catechol O-Methyltransferase Inhibitors, Anticholinergics, Amantadine), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, And Africa) – Share, Size, Outlook, And Opportunity Analysis, 2023-2030.
According to Pharmanucleus the immunotherapy drugs market is projected to achieve a Compound Annual Growth Rate (CAGR) of 8.70% between 2023 and 2030. Immunotherapy, a type of cancer treatment, enhances the body's innate immune system to combat cancer cells. It utilizes substances produced by the body or generated in vitro in the laboratory.
The Osteosarcoma market is projected to grow significantly in the coming years. The market, which was valued at USD 632.62 Mn in 2023, is anticipated to reach USD 1404.20 Mn by 2033, reflecting a compound annual growth rate (CAGR) of 8.3% during the forecast period of 2024 to 2033.
The Non-Alcoholic Fatty Liver Disease market is projected to grow significantly in the coming years. The market, which was valued at USD 1.6 Bn in 2023, is anticipated to reach USD 13.95 Bn by 2033, reflecting a compound annual growth rate (CAGR) of 24.18% during the forecast period of 2024 to 2033.
The Non-Hodgkin Lymphoma (NHL) market is projected to grow significantly in the coming years. The market, which was valued at USD 9.81 Bn in 2023, is anticipated to reach USD 22.18 Bn by 2033, reflecting a compound annual growth rate (CAGR) of 8.50% during the forecast period of 2024 to 2033.
The Chemotherapy Induced Anemia market is projected to grow significantly in the coming years. The market, which was valued at USD 2.41 Bn in 2023, is anticipated to reach USD 4.83 Bn by 2033, reflecting a compound annual growth rate (CAGR) of 7.2% during the forecast period of 2024 to 2033.
The Follicular Lymphoma market is projected to grow significantly in the coming years. The market, which was valued at USD 1495.23 Mn in 2023, is anticipated to reach USD 2366.87 Mn by 2033, reflecting a compound annual growth rate (CAGR) of 4.7% during the forecast period of 2024 to 2033.
The Inflammatory Bowel Diseases (IBD) market is projected to grow significantly in the coming years. The market, which was valued at USD 22.42 Bn in 2023, is anticipated to reach USD 37.58 Bn by 2033, reflecting a compound annual growth rate (CAGR) of 5.3% during the forecast period of 2024 to 2033.
The Gastritis market is projected to grow significantly in the coming years. The market, which was valued at USD 175.44 Mn in 2023, is anticipated to reach USD 259.69 Mn by 2033, reflecting a compound annual growth rate (CAGR) of 4.0% during the forecast period of 2024 to 2033.
The Liver Function Test market is projected to grow significantly in the coming years. The market, which was valued at USD 38.24 Bn in 2023, is anticipated to reach USD 75.22 Bn by 2033, reflecting a compound annual growth rate (CAGR) of 7.0% during the forecast period of 2024 to 2033.
The Uterine Cancer Drugs market is projected to grow significantly in the coming years. The market, which was valued at USD 2.6 Mn in 2023, is anticipated to reach USD 5.88 Mn by 2033, reflecting a compound annual growth rate (CAGR) of 8.5% during the forecast period of 2024 to 2033.
The Age-Related Macular Degeneration (AMD) Disease - Anti VEGF market is projected to grow significantly in the coming years. The market, which was valued at USD 12.78 Bn in 2023, is anticipated to reach USD 18.74 Bn by 2033, reflecting a compound annual growth rate (CAGR) of 3.9% during the forecast period of 2024 to 2033.
The Visceral Pain market is projected to grow significantly in the coming years. The market, which was valued at USD 13.71 Bn in 2023, is anticipated to reach USD 23.87 Bn by 2033, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period of 2024 to 2033.
The AI in Neurology market is projected to grow significantly in the coming years. The market, which was valued at USD 48.0 Mn in 2023, is anticipated to reach USD 1,408.38 Mn by 2033, reflecting a compound annual growth rate (CAGR) of 40.2% during the forecast period of 2024 to 2033.
The Pediatric Growth Hormone Deficiency market is projected to grow significantly in the coming years. The market, which was valued at USD 3.45 Bn in 2023, is anticipated to reach USD 13.96 Bn by 2033, reflecting a compound annual growth rate (CAGR) of 15.0% during the forecast period of 2024 to 2033.
The Cluster Headache Drugs market is projected to grow significantly in the coming years. The market, which was valued at USD 369.14 Mn in 2023, is anticipated to reach USD 692.93 Mn by 2033, reflecting a compound annual growth rate (CAGR) of 6.5% during the forecast period of 2024 to 2033.
The Lyophilized Injectable Drugs market is projected to grow significantly in the coming years. The market, which was valued at USD 3,196.39 Mn in 2023, is anticipated to reach USD 5,833.17 Mn by 2033, reflecting a compound annual growth rate (CAGR) of 6.2% during the forecast period of 2024 to 2033.
The Down Syndrome market is projected to grow significantly in the coming years. The market, which was valued at USD 1,796.27 Mn in 2023, is anticipated to reach USD 6,776.92 Mn by 2033, reflecting a compound annual growth rate (CAGR) of 14.2% during the forecast period of 2024 to 2033.
The Live Attenuated Vaccines market is projected to grow significantly in the coming years. The market, which was valued at USD 18,932.8 Mn in 2023, is anticipated to reach USD 60396.59 Mn by 2033, reflecting a compound annual growth rate (CAGR) of 12.3% during the forecast period of 2024 to 2033.
The Advanced Melanoma market is projected to grow significantly in the coming years. The market, which was valued at USD 3.9 Bn in 2023, is anticipated to reach USD 9.15 Bn by 2033, reflecting a compound annual growth rate (CAGR) of 8.9% during the forecast period of 2024 to 2033.
The Advanced Liver Cancer market is projected to grow significantly in the coming years. The market, which was valued at USD 8,008.8 Mn in 2023, is anticipated to reach USD 15,033.62 Mn by 2033, reflecting a compound annual growth rate (CAGR) of 6.5% during the forecast period of 2024 to 2033.
The Adult T-Cell Leukemia Lymphoma market is projected to grow significantly in the coming years. The market, which was valued at USD 1,915.46 Mn in 2023, is anticipated to reach USD 4,330.82 Mn by 2033, reflecting a compound annual growth rate (CAGR) of 8.5% during the forecast period of 2024 to 2033.
The Adult Myopia market is projected to grow significantly in the coming years. The market, which was valued at USD 19.25 Bn in 2023, is anticipated to reach USD 41.56 Bn by 2033, reflecting a compound annual growth rate (CAGR) of 8.0% during the forecast period of 2024 to 2033.
The Adrenocortical Carcinoma market is projected to grow significantly in the coming years. The market, which was valued at USD 672.3 Mn in 2023, is anticipated to reach USD 860.6 Mn by 2033, reflecting a compound annual growth rate (CAGR) of 2.5% during the forecast period of 2024 to 2033.
The Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market is projected to grow significantly in the coming years. The market, which was valued at USD 5.2 Bn in 2023, is anticipated to reach USD 21.2 Bn by 2033, reflecting a compound annual growth rate (CAGR) of 15.1% during the forecast period of 2024 to 2033.
The Acute Respiratory Distress Syndrome (ARDS) market is projected to grow significantly in the coming years. The market, which was valued at USD 3.1 Bn in 2023, is anticipated to reach USD 5.35 Bn by 2033, reflecting a compound annual growth rate (CAGR) of 5.6% during the forecast period of 2024 to 2033.
The Acute Pulmonary Embolism market is projected to grow significantly in the coming years. The market, which was valued at USD 1.79 Bn in 2023, is anticipated to reach USD 3.97 Bn by 2033, reflecting a compound annual growth rate (CAGR) of 8.3% during the forecast period of 2024 to 2033.
The Severe Asthma market is projected to grow significantly in the coming years. The market, which was valued at USD 22 Bn in 2023, is anticipated to reach USD 36.18 Bn by 2033, reflecting a compound annual growth rate (CAGR) of 5.1% during the forecast period of 2024 to 2033.
The Tardive Dyskinesia market is projected to grow significantly in the coming years. The market, which was valued at USD 3.59 Bn in 2023, is anticipated to reach USD 8.74 Bn by 2033, reflecting a compound annual growth rate (CAGR) of 9.3% during the forecast period of 2024 to 2033.
The Soft Tissue Sarcoma market is projected to grow significantly in the coming years. The market, which was valued at USD 3,989.52 Mn in 2023, is anticipated to reach USD 8,533.66 Mn by 2033, reflecting a compound annual growth rate (CAGR) of 7.9% during the forecast period of 2024 to 2033.
The Small Cell Lung Cancer market is projected to grow significantly in the coming years. The market, which was valued at USD 12.1 Bn in 2023, is anticipated to reach USD 31.3 Bn by 2033, reflecting a compound annual growth rate (CAGR) of 10.0% during the forecast period of 2024 to 2033.
The Sepsis market is projected to grow significantly in the coming years. The market, which was valued at USD 3.8 Bn in 2023, is anticipated to reach USD 8.5 Bn by 2033, reflecting a compound annual growth rate (CAGR) of 8.5% during the forecast period of 2024 to 2033.
The Schizophrenia market is projected to grow significantly in the coming years. The market, which was valued at USD 9,480.40 Mn in 2023, is anticipated to reach USD 14,582.49 Mn by 2033, reflecting a compound annual growth rate (CAGR) of 4.4% during the forecast period of 2024 to 2033.
The Pulmonary Arterial Hypertension market is projected to grow significantly in the coming years. The market, which was valued at USD 7.66 Bn in 2023, is anticipated to reach USD 12.96 Bn by 2033, reflecting a compound annual growth rate (CAGR) of 5.4% during the forecast period of 2024 to 2033.
The Presbyopia market is projected to grow significantly in the coming years. The market, which was valued at USD 10.34 Bn in 2023, is anticipated to reach USD 16.6 Bn by 2033, reflecting a compound annual growth rate (CAGR) of 4.9% during the forecast period of 2024 to 2033.
The Open Angle Glaucoma market is projected to grow significantly in the coming years. The market, which was valued at USD 5.4 Mn in 2023, is anticipated to reach USD 7.99 Mn by 2033, reflecting a compound annual growth rate (CAGR) of 4.0% during the forecast period of 2024 to 2033.
The Onychomycosis market is projected to grow significantly in the coming years. The market, which was valued at USD 3.58 Bn in 2023, is anticipated to reach USD 5.35 Bn by 2033, reflecting a compound annual growth rate (CAGR) of 4.1% during the forecast period of 2024 to 2033.
The Natural Killer (NK) Cell Therapeutics market is projected to grow significantly in the coming years. The market, which was valued at USD 3,126.72 Mn in 2023, is anticipated to reach USD 15,551.42 Mn by 2033, reflecting a compound annual growth rate (CAGR) of 17.4% during the forecast period of 2024 to 2033.
The Nasopharyngeal Cancer market is projected to grow significantly in the coming years. The market, which was valued at USD 616.22 Mn in 2023, is anticipated to reach USD 1.2 Bn by 2033, reflecting a compound annual growth rate (CAGR) of 7.3% during the forecast period of 2024 to 2033.
The Migraine market is projected to grow significantly in the coming years. The market, which was valued at USD 3.89 Bn in 2023, is anticipated to reach USD 16.58 Bn by 2033, reflecting a compound annual growth rate (CAGR) of 15.6% during the forecast period of 2024 to 2033.
The Metastatic Colorectal Cancer market is projected to grow significantly in the coming years. The market, which was valued at USD 3.5 Bn in 2023, is anticipated to reach USD 5.49 Bn by 2033, reflecting a compound annual growth rate (CAGR) of 4.6% during the forecast period of 2024 to 2033.
The Malignant Mesothelioma market is projected to grow significantly in the coming years. The market, which was valued at USD 285.14 Mn in 2023, is anticipated to reach USD 675.03 Mn by 2033, reflecting a compound annual growth rate (CAGR) of 9.0% during the forecast period of 2024 to 2033.
The Liver Cancer market is projected to grow significantly in the coming years. The market, which was valued at USD 9,339.6 Mn in 2023, is anticipated to reach USD 17,813.58 Mn by 2033, reflecting a compound annual growth rate (CAGR) of 6.67% during the forecast period of 2024 to 2033.
The Hypothalamic Obesity market is projected to grow significantly in the coming years. The market, which was valued at USD 356.3 Mn in 2023, is anticipated to reach USD 820.56 Mn by 2033, reflecting a compound annual growth rate (CAGR) of 8.7% during the forecast period of 2024 to 2033.
The Hepatocellular Carcinoma market is projected to grow significantly in the coming years. The market, which was valued at USD 1.13 Bn in 2023, is anticipated to reach USD 2.49 Bn by 2033, reflecting a compound annual growth rate (CAGR) of 11.1% during the forecast period of 2024 to 2033.
The Hepatitis C market is projected to grow significantly in the coming years. The market, which was valued at USD 62.6 Bn in 2023, is anticipated to reach USD 224.06 Bn Mn by 2033, reflecting a compound annual growth rate (CAGR) of 13.6% during the forecast period of 2024 to 2033.
The Hepatitis B market is projected to grow significantly in the coming years. The market, which was valued at USD 4.63 Bn in 2023, is anticipated to reach USD 6.45 Bn by 2033, reflecting a compound annual growth rate (CAGR) of 3.37% during the forecast period of 2024 to 2033.
The Gastroparesis market is projected to grow significantly in the coming years. The market, which was valued at USD 8,352.13 Mn in 2023, is anticipated to reach USD 11,895.83 Mn by 2033, reflecting a compound annual growth rate (CAGR) of 3.6% during the forecast period of 2024 to 2033.
The Dry Age-Related Macular Degeneration market is projected to grow significantly in the coming years. The market, which was valued at USD 9.54 Bn in 2023, is anticipated to reach USD 20.9 Bn by 2033, reflecting a compound annual growth rate (CAGR) of 8.2% during the forecast period of 2024 to 2033.
The Dementia market is projected to grow significantly in the coming years. The market, which was valued at USD 15.48 Bn in 2023, is anticipated to reach USD 30 Bn by 2033, reflecting a compound annual growth rate (CAGR) of 6.2% during the forecast period of 2024 to 2033.
The Chronic Wounds market is projected to grow significantly in the coming years. The market, which was valued at USD 13.3 Bn in 2023, is anticipated to reach USD 19.82 Bn by 2033, reflecting a compound annual growth rate (CAGR) of 4.07% during the forecast period of 2024 to 2033.
The Chronic Lower Back Pain market is projected to grow significantly in the coming years. The market, which was valued at USD 9,789.3 Mn in 2023, is anticipated to reach USD 17,458.2 Mn by 2033, reflecting a compound annual growth rate (CAGR) of 5.4% during the forecast period of 2024 to 2033.
The Cervical Cancer market is projected to grow significantly in the coming years. The market, which was valued at USD 1.6 Bn in 2023, is anticipated to reach USD 5.7 Bn by 2033, reflecting a compound annual growth rate (CAGR) of 13.7% during the forecast period of 2024 to 2033.
The Car T Cell Therapy for Multiple Myeloma market is projected to grow significantly in the coming years. The market, which was valued at USD 720.3 Mn in 2023, is anticipated to reach USD 3999.64 Mn by 2033, reflecting a compound annual growth rate (CAGR) of 18.7% during the forecast period of 2024 to 2033.
The Brain Cancer market is projected to grow significantly in the coming years. The market, which was valued at USD 1.8 Bn in 2023, is anticipated to reach USD 3.19 Bn by 2033, reflecting a compound annual growth rate (CAGR) of 5.9% during the forecast period of 2024 to 2033.
The Atrial Fibrillation market is projected to grow significantly in the coming years. The market, which was valued at USD 10.8 Bn in 2023, is anticipated to reach USD 19.3 Bn by 2033, reflecting a compound annual growth rate (CAGR) of 6.0% during the forecast period of 2024 to 2033.
The Spinal Cord Injury Epidemiology market is projected to grow significantly in the coming years. The market, which was valued at USD 7.2 Bn in 2023, is anticipated to reach USD 11.8 Bn by 2033, reflecting a compound annual growth rate (CAGR) of 5.1% during the forecast period of 2024 to 2033.
The Allergic Conjunctivitis market is projected to grow significantly in the coming years. The market, which was valued at USD 4,176.62 Mn in 2023, is anticipated to reach USD 7,409.43 Mn by 2033, reflecting a compound annual growth rate (CAGR) of 5.9% during the forecast period of 2024 to 2033.
The Spinal Muscular Atrophy market is projected to grow significantly in the coming years. The market, which was valued at USD 1813.48 Mn in 2023, is anticipated to reach USD 6,321.38 Mn by 2033, reflecting a compound annual growth rate (CAGR) of 13.3% during the forecast period of 2024 to 2033.
The Prostate Cancer market is projected to grow significantly in the coming years. The market, which was valued at USD 10.92 Bn in 2023, is anticipated to reach USD 24.7 Bn by 2033, reflecting a compound annual growth rate (CAGR) of 8.5% during the forecast period of 2024 to 2033.
The Pancreatic Cancer market is projected to grow significantly in the coming years. The market, which was valued at USD 2,125.57 Mn in 2023, is anticipated to reach USD 7,541.09 Mn by 2033, reflecting a compound annual growth rate (CAGR) of 13.5% during the forecast period of 2024 to 2033.
The Multiple Sclerosis market is projected to grow significantly in the coming years. The market, which was valued at USD 26.5 Bn in 2023, is anticipated to reach USD 38.1 Bn by 2033, reflecting a compound annual growth rate (CAGR) of 3.7% during the forecast period of 2024 to 2033.
The Multiple Myeloma market is projected to grow significantly in the coming years. The market, which was valued at USD 25 Bn in 2023, is anticipated to reach USD 46.9 Bn by 2033, reflecting a compound annual growth rate (CAGR) of 6.5% during the forecast period of 2024 to 2033.
The Epilepsy market is projected to grow significantly in the coming years. The market, which was valued at USD 2300.00 Mn in 2023, is anticipated to reach USD 4482.34 Mn by 2033, reflecting a compound annual growth rate (CAGR) of 6.9% during the forecast period of 2024 to 2033.
The Cystic Fibrosis market is projected to grow significantly in the coming years. The market, which was valued at USD 6.1 Bn in 2023, is anticipated to reach USD 17.3 Bn by 2033, reflecting a compound annual growth rate (CAGR) of 11.0% during the forecast period of 2024 to 2033.
The Idiopathic Pulmonary Fibrosis market is projected to grow significantly in the coming years. The market, which was valued at USD 4 Bn in 2023, is anticipated to reach USD 7.4 Bn by 2033, reflecting a compound annual growth rate (CAGR) of 6.4% during the forecast period of 2024 to 2033.
The Dry Eye Disease market is projected to grow significantly in the coming years. The market, which was valued at USD 6.5 Bn in 2023, is anticipated to reach USD 13.2 Bn by 2033, reflecting a compound annual growth rate (CAGR) of 7.4% during the forecast period of 2024 to 2033.
The Antimicrobial Susceptibility Testing market is projected to grow significantly in the coming years. The market, which was valued at USD 3.8 Bn in 2023, is anticipated to reach USD 6.4 Bn by 2033, reflecting a compound annual growth rate (CAGR) of 5.5% during the forecast period of 2024 to 2033.
The Acute Ischemic Stroke (AIS) market is projected to grow significantly in the coming years. The market, which was valued at USD 1481.4 Mn in 2023, is anticipated to reach USD 2833.46 Mn by 2033, reflecting a compound annual growth rate (CAGR) of 6.7% during the forecast period of 2024 to 2033.
The Herpes Labialis market is projected to grow significantly in the coming years. The market, which was valued at USD 1.13 Bn in 2023, is anticipated to reach USD 1.79 Bn by 2033, reflecting a compound annual growth rate (CAGR) of 4.7% during the forecast period of 2024 to 2033.
The HER-2 Positive Gastric Cancer market is projected to grow significantly in the coming years. The market, which was valued at USD 1261.8 Mn in 2023, is anticipated to reach USD 1779.8 Mn by 2033, reflecting a compound annual growth rate (CAGR) of 3.5% during the forecast period of 2024 to 2033.
The HER-2 Positive Early Breast Cancer market is projected to grow significantly in the coming years. The market, which was valued at USD 10.8 Bn in 2023, is anticipated to reach USD 22.4 Bn by 2033, reflecting a compound annual growth rate (CAGR) of 7.6% during the forecast period of 2024 to 2033.
The Hepatitis B Virus (HBV) Infection market is projected to grow significantly in the coming years. The market, which was valued at USD 4.9 Bn in 2023, is anticipated to reach USD 7.11 Bn by 2033, reflecting a compound annual growth rate (CAGR) of 3.8% during the forecast period of 2024 to 2033.
The Hepatic Encephalopathy market is projected to grow significantly in the coming years. The market, which was valued at USD 1486.39 Mn in 2023, is anticipated to reach USD 2971.51 Mn by 2033, reflecting a compound annual growth rate (CAGR) of 6.5% during the forecast period of 2024 to 2033.
The Glioblastoma market is projected to grow significantly in the coming years. The market, which was valued at USD 2.65 Bn in 2023, is anticipated to reach USD 6.57 Bn by 2033, reflecting a compound annual growth rate (CAGR) of 9.5% during the forecast period of 2024 to 2033.
The Glaucoma market is projected to grow significantly in the coming years. The market, which was valued at USD 8.6 Bn in 2023, is anticipated to reach USD 13.48 Bn by 2033, reflecting a compound annual growth rate (CAGR) of 4.6% during the forecast period of 2024 to 2033.
The Nuclear Medicine/ Radio-pharmaceuticals market is projected to grow significantly in the coming years. The market, which was valued at USD 5.3 Bn in 2023, is anticipated to reach USD 15.5 Bn by 2033, reflecting a compound annual growth rate (CAGR) of 11.0% during the forecast period of 2024 to 2033.
The Obesity Management market is projected to grow significantly in the coming years. The market, which was valued at USD 2095.6 Mn in 2023, is anticipated to reach USD 3479.09 Mn by 2033, reflecting a compound annual growth rate (CAGR) of 5.2% during the forecast period of 2024 to 2033.
The Liposome Drug Delivery market is projected to grow significantly in the coming years. The market, which was valued at USD 4.50 Bn in 2023, is anticipated to reach USD 10.17 Bn by 2033, reflecting a compound annual growth rate (CAGR) of 8.5% during the forecast period of 2024 to 2033.
The Laboratory Automation market is projected to grow significantly in the coming years. The market, which was valued at USD 5.3 Bn in 2023, is anticipated to reach USD 9.5 Bn by 2033, reflecting a compound annual growth rate (CAGR) of 5.5% during the forecast period of 2024 to 2033.
The High Potency API market is projected to grow significantly in the coming years. The market, which was valued at USD 25.2 Bn in 2023, is anticipated to reach USD 59.9 Bn by 2033, reflecting a compound annual growth rate (CAGR) of 10.1% during the forecast period of 2024 to 2033.
The Orphan Drugs market is projected to grow significantly in the coming years. The market, which was valued at USD 1.5 Bn in 2023, is anticipated to reach USD 4.7 Bn by 2033, reflecting a compound annual growth rate (CAGR) of 10.4% during the forecast period of 2024 to 2033.
The Genetic Toxicity Testing market is projected to grow significantly in the coming years. The market, which was valued at USD 1.8 Bn in 2023, is anticipated to reach USD 4.75 Bn by 2033, reflecting a compound annual growth rate (CAGR) of 10.2% during the forecast period of 2024 to 2033.
The Fragment-based Drug Delivery market is projected to grow significantly in the coming years. The market, which was valued at USD 1.1 Bn in 2023, is anticipated to reach USD 3.12 Bn by 2033, reflecting a compound annual growth rate (CAGR) of 11.0% during the forecast period of 2024 to 2033.
The CRO (Contract Research Organization) Services market is projected to grow significantly in the coming years. The market, which was valued at USD 75.5 Bn in 2023, is anticipated to reach USD 53.66 Bn by 2033, reflecting a compound annual growth rate (CAGR) of 10.1% during the forecast period of 2024 to 2033.
The Benign Breast Disease and Early Breast Cancer market is projected to grow significantly in the coming years. The market, which was valued at USD 8500.0 Mn in 2023, is anticipated to reach USD 9864.6 Mn by 2033, reflecting a compound annual growth rate (CAGR) of 1.5% during the forecast period of 2024 to 2033.
The Antisense & RNAi Therapeutics market is projected to grow significantly in the coming years. The market, which was valued at USD 4.12 Bn in 2023, is anticipated to reach USD 22.69 Bn by 2033, reflecting a compound annual growth rate (CAGR) of 4.12% during the forecast period of 2024 to 2033.
The Gastric Ulcers market is projected to grow significantly in the coming years. The market, which was valued at USD 4.57 Bn in 2023, is anticipated to reach USD 6.96 bn by 2033, reflecting a compound annual growth rate (CAGR) of 4.3% during the forecast period of 2024 to 2033.
The Gastric Neuroendocrine Tumors market is projected to grow significantly in the coming years. The market, which was valued at USD 2689.87 Mn in 2023, is anticipated to reach USD 7300.53 Mn by 2033, reflecting a compound annual growth rate (CAGR) of 10.5% during the forecast period of 2024 to 2033.
The Filariasis market is projected to grow significantly in the coming years. The market, which was valued at USD 10.96 Bn in 2023, is anticipated to reach USD 28.68 Bn by 2033, reflecting a compound annual growth rate (CAGR) of 10.1% during the forecast period of 2024 to 2033.
The Fibromyalgia market is projected to grow significantly in the coming years. The market, which was valued at USD 2.8 Bn Mn in 2023, is anticipated to reach USD 5.4 Bn by 2033, reflecting a compound annual growth rate (CAGR) of 6.8% during the forecast period of 2024 to 2033.
The Familial Chylomicronemia Syndrome market is projected to grow significantly in the coming years. The market, which was valued at USD 17 Mn in 2023, is anticipated to reach USD 35.3 Mn by 2033, reflecting a compound annual growth rate (CAGR) of 15.3% during the forecast period of 2024 to 2033.
The Fallopian Tube Cancer market is projected to grow significantly in the coming years. The market, which was valued at USD 3.5 Bn in 2023, is anticipated to reach USD 14.5 Bn by 2033, reflecting a compound annual growth rate (CAGR) of 15.3% during the forecast period of 2024 to 2033.
The Eosinophilia market is projected to grow significantly in the coming years. The market, which was valued at USD 410 Mn in 2023, is anticipated to reach USD 734.25 Mn by 2033, reflecting a compound annual growth rate (CAGR) of 6.0% during the forecast period of 2024 to 2033.
The Drug Discovery Services market is projected to grow significantly in the coming years. The market, which was valued at USD 20.5 Bn in 2023, is anticipated to reach USD 53.66 Bn by 2033, reflecting a compound annual growth rate (CAGR) of 10.1% during the forecast period of 2024 to 2033.
The Developmental and Epileptic Encephalopathies (DEE) market is projected to grow significantly in the coming years. The market, which was valued at USD 7 Bn in 2023, is anticipated to reach USD 11.6 Bn by 2033, reflecting a compound annual growth rate (CAGR) of 5.2% during the forecast period of 2024 to 2033.
The Continuous Manufacturing market is projected to grow significantly in the coming years. The market, which was valued at USD 430.2 Mn in 2023, is anticipated to reach USD 972.7 Mn by 2033, reflecting a compound annual growth rate (CAGR) of 8.5% during the forecast period of 2024 to 2033.
The Chronic Pain market is projected to grow significantly in the coming years. The market, which was valued at USD 71.6 Bn in 2023, is anticipated to reach USD 138.39 Bn by 2033, reflecting a compound annual growth rate (CAGR) of 6.8% during the forecast period of 2024 to 2033.
The Corneal Endothelial Dystrophy market is projected to grow significantly in the coming years. The market, which was valued at USD 170 Bn in 2023, is anticipated to reach USD 350.38 Bn by 2033, reflecting a compound annual growth rate (CAGR) of 7.5% during the forecast period of 2024 to 2033.
The Car T-Cell Therapy for Acute Lymphoblastic Leukemia market is projected to grow significantly in the coming years. The market, which was valued at USD 2.8 Bn in 2023, is anticipated to reach USD 28.6 Bn by 2033, reflecting a compound annual growth rate (CAGR) of 26.2% during the forecast period of 2024 to 2033.
The Cancer Vaccines market is projected to grow significantly in the coming years. The market, which was valued at USD 9.50 Bn in 2023, is anticipated to reach USD 18.98 Bn Mn by 2033, reflecting a compound annual growth rate (CAGR) of 5.1% during the forecast period of 2024 to 2033.
The Community Acquired Bacterial Pneumonia (CABP) market is projected to grow significantly in the coming years. The market, which was valued at USD 5 Bn in 2023, is anticipated to reach USD 8.3 Bn by 2033, reflecting a compound annual growth rate (CAGR) of 5.2% during the forecast period of 2024 to 2033.
The Bronchiolitis Obliterans Syndrome market is projected to grow significantly in the coming years. The market, which was valued at USD 60 Mn in 2023, is anticipated to reach USD 98.67 Mn by 2033, reflecting a compound annual growth rate (CAGR) of 5.1% during the forecast period of 2024 to 2033.
The Biosimilars market is projected to grow significantly in the coming years. The market, which was valued at USD 29.1 Bn in 2023, is anticipated to reach USD 122.75 Bn by 2033, reflecting a compound annual growth rate (CAGR) of 15.5% during the forecast period of 2024 to 2033.
The Biologics Contract Manufacturing market is projected to grow significantly in the coming years. The market, which was valued at USD 16.4 Bn in 2023, is anticipated to reach USD 36.40 Bn by 2033, reflecting a compound annual growth rate (CAGR) of 8.3% during the forecast period of 2024 to 2033.
The Acute Myeloid Leukemia market is projected to grow significantly in the coming years. The market, which was valued at USD 1.50 Bn in 2023, is anticipated to reach USD 3.25 Bn by 2033, reflecting a compound annual growth rate (CAGR) of 10.0% during the forecast period of 2024 to 2033.
The Acute Heart Failure (AHF) market is projected to grow significantly in the coming years. The market, which was valued at USD 270.6 Mn in 2023, is anticipated to reach USD 2622.8 Mn by 2033, reflecting a compound annual growth rate (CAGR) of 25.5% during the forecast period of 2024 to 2033.
The Endoscopic Equipment market is projected to grow significantly in the coming years. The market, which was valued at USD 30 Bn in 2023, is anticipated to reach USD 59 Bn by 2033, reflecting a compound annual growth rate (CAGR) of 7.0% during the forecast period of 2024 to 2033.
The Clear Cell HER2 Non-Small Cell Lung Cancer market is projected to grow significantly in the coming years. The market, which was valued at USD 5.2 Bn in 2023, is anticipated to reach USD 9.4 Bn by 2033, reflecting a compound annual growth rate (CAGR) of 6.2% during the forecast period of 2024 to 2033.
According to industry analyst Pharmanucleus, the global urothelial carcinoma treatment market is expected to witness robust growth during the forecast period from 2023 to 2030. The projected compound annual growth rate (CAGR) for the market is estimated to be around 20%. In 2022, the market was valued at USD 0.81 billion, and it is predicted to reach USD 3.48 billion by 2030.
According to Pharmanucleus, the tumor infiltrating lymphocytes (TILs) market is projected to grow significantly in the coming years. The market, which was valued at USD 9.17 billion in 2022, is anticipated to reach USD 25.5 billion by 2030, reflecting a compound annual growth rate (CAGR) of 12.00% during the forecast period of 2023 to 2030.
The overall market size of Polycythemia Vera in the United States is expected to expand at a CAGR of 14% during the research period (2023-2030).PV is a condition that causes an increase in the amount of red blood cells in the bloodstream from a variety of factors. Itching, headache, dizziness, fatigue, blind spots, leukaemia, and, in rare cases, a heart attack induced by an atypical thrombotic event are all visible signs.
The pediatric brain tumor market is growing at a CAGR of 6.8% over the forecast period and is expected to reach USD 1,843.7 million by 2022-2030. Pediatric brain tumor is an uncontrolled or abnormal growth of normal cells in the brain in children. Brain tumors are mainly of two types, cancerous (malignant) and non-cancerous (benign).
The global ovarian cancer market is expected to witness significant growth over the forecast period. Emerging markets and huge investments in research and development are the factors responsible for the growth of this market. Multiple therapeutic landscapes and family history of ovarian cancer are seen as positive indicators of demand for new ovarian cancer drugs.
The Neuroendocrine Tumor Market is expected to witness market growth during the forecast period of 2023 to 2030. Pharmanucleusanalyzes that the market is growing with a CAGR of 10.4% during the forecast period of 2023 to 2030 and is expected to to reach USD 5,300.53 million by 2030.
The Global Neuroendocrine Carcinoma Treatment market is expected to reach US$ 1.7 billion by 2022, with a CAGR of 8.0% indicating favourable market expansion throughout the projected period.This report provides a comprehensive analysis of the global neuroendocrine tumor treatment market.
The global infection control market in terms of revenue was estimated to be worth $50.0 billion in 2023 and is poised to reach $58.3 billion by 2030, growing at a CAGR of 3.1% from 2023 to 2030.The new research study consists of an analysis of market industry trends. The new research study includes industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behavior in the market.
The HPV16 anogenital cancers market is projected to experience a high compound annual growth rate CAGR~1% from 2023 to 2030. This specialized sector of oncology focuses on the diagnosis, treatment, and management of anogenital cancers caused by HPV16, a high-risk strain of the human papillomavirus.
Hodgkin's lymphoma (HL) is a specific type of cancer affecting the lymphatic system, characterized by the presence of Reed-Sternberg cells in the lymph nodes. These abnormal cells play a crucial role in HL diagnosis. The HL market encompasses various products and services related to the diagnosis, treatment, and management of this disease.
The global HLA typing market in terms of revenue was estimated to be worth $1.4 billion in 2022 and is poised to reach $2.1 billion by 2028, growing at a CAGR of 6.5% from 2022 to 2028. The new research study includes a market industry trend analysis. The new study report covers industry trends, price analysis, patent analysis, conference and webinar materials, important stakeholders, and market purchasing behaviour.
Pharmanucleus, a research organization, has conducted an analysis on the projected growth rate of the global gastric cancer market for the forecast period of 2023-2030. According to their findings, the market is expected to experience a Compound Annual Growth Rate (CAGR) of approximately 16% during this period.
The Fuchs Endothelial Corneal Dystrophy Market is predicted to grow throughout the forecast period of 2023-2030. In order to assume growth at a CAGR of 8.40% throughout the previously predicted period, Pharmanucleus undertakes a market study.
The global FGFR Positive Gastroesophageal Cancer Market size was valued at $YY million in 2022 and is projected to reach $YY million by 2030, growing at a high CAGR during the forecast period from 2023 to 2030.The FGFR (fibroblast growth factor receptor) positive gastroesophageal cancer market encompasses the pharmaceutical and biotechnology products specifically designed to target FGFR gene alterations in patients with gastroesophageal cancer.
The global ESR1 Mutation Metastatic Breast Cancer Diagnostics Market generated a Market Value of US$58.70 Million in 2022 and is expected to accumulate a Market Value of US$185 Million by registering a CAGR of 11% during the forecast period 2023 to 2030.
The global sarcoma market size was valued at $YY million in 2022 and is projected to reach $YY million by 2030, growing at a CAGR of 8.3% from 2023 to 2030.Epithelioid sarcoma is a rare and aggressive soft tissue sarcoma that primarily affects young adults. The market for epithelioid sarcoma treatment is relatively small due to its low incidence, presenting limited commercial opportunities for pharmaceutical companies.
The epithelial ovarian cancer market is growing steadily owing to the rising incidence of this malignancy. Epithelial ovarian cancer, the most common type of ovarian cancer, poses significant health risks to women worldwide. The market is driven by advances in treatment options such as surgery, chemotherapy, targeted therapy and immunotherapy which improve patient outcomes.
The Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Market is a rapidly evolving sector within the field of lung cancer therapeutics. EGFR-NSCLC is a distinct subtype of non-small cell lung cancer characterized by specific genetic mutations affecting the EGFR gene.
The Endometrial Cancer Market is anticipated to reach USD 22,187.69 Million by 2030 at 4.20% CAGR during the forecast period 2023-2030. Endometrial cancer, commonly known as uterine cancer, is the abnormal development of endometrium cells in the uterus. Women with abnormal vaginal bleeding are diagnosed with endometrial cancer at an early stage.
The Diffuse Large B-cell Lymphoma (DLBCL) Therapeutics Market refers to the market for drugs and therapies used in the treatment of diffuse large B-cell lymphoma, which is a type of aggressive non-Hodgkin lymphoma. The market size of DLBCL therapeutics was valued at USD 4,107.50 million in 2021.
Pharmanucleusanalyzes a growth rate of the diabetic neuropathy market over the forecast period 2023-2030. The expected CAGR of the diabetic neuropathy market tends to be around 6.9% during the mentioned forecast period. The market was valued at USD 3876.6 Million in 2022, and it will reach USD 6611.08 Million by 2030.
Pharmanucleusanalyzes a growth rate of the Dengue Vaccine market over the forecast period 2023-2030. The expected CAGR of the dengue fever vaccine market tends to be around 11.7% during the mentioned forecast period. The market was valued at USD 0.53 Billion in 2022 and it will reach USD 1.28 Billion by 2030.
The Dementia Drugs Market size was valued at $8.7 billion in 2023, and is projected to reach $19.7 billion by 2030, growing at a CAGR of 8.5% from 2022 to 2030.Dementia causes a decline in mental function from a previously higher level that is severe enough to interfere with daily life.
Crohn's Disease Market size was valued at USD 11.1 Billion in 2022 and is projected to grow from USD 11.5 Billion in 2023 to USD 14.3 Billion by 2030, growing at a compound annual growth rate (CAGR ) by 3.70% over the forecast period (2023 - 2030). One of the major market drivers fueling the expansion of the market is the rising prevalence of Crohn's disease due to changes in people's lifestyles.
Coronary microvascular dysfunction (CMD) refers to a condition characterized by abnormalities in the small blood vessels of the heart, resulting in impaired blood flow to the heart muscle. CMD is a significant health problem because it can lead to chest pain, heart attacks, and heart failure.
Pharmanucleusanalyzes a growth rate of the global congestive heart failure market over the forecast period 2023-2030. The expected CAGR of the global congestive heart failure market tends to be around 7.0% during the mentioned forecast period. The market was valued at USD 21 Billion in 2021, and it will reach USD 36.08 Billion by 2030.
The global market for complex regional pain syndrome (CRPS) is estimated to be worth US$ 101.9 Million in 2023, rising to US$ 126.7 Million by 2030. During the projection period of 2023 to 2030, the market is forecast to grow at a CAGR of 2.2%.The increase in the number of people suffering from the complex regional pain syndrome (CRPS), chronic pain and back failure syndrome is one of the major reasons for the development of the market.
The colorectal cancer market is expected to grow from US$ 18,619.3 million in 2023 to US$ 24,078.5 million by 2030; it is expected to grow at a CAGR of 3.3% from 2023 to 2030.Factors such as increasing prevalence of colorectal cancer, product launches, and benefits offered by generic drugs are driving the growth of the global colorectal cancer market.
Clear Cell Ovarian CancerMarket size was valued at USD 1.57 billion in 2021 and is poised to grow from USD 1.77 billion in 2022 to USD 9.67 billion by 2030, growing at a CAGR of 23.7% in the forecast period (2023-2030).Clear cell ovarian cancer is a rare subtype of ovarian cancer characterized by the presence of clear cells in the tumor. It accounts for approximately 5-10% of all ovarian cancer cases.
Global Chronic Rhinosinusitis Market was valued at USD 2,132.5 Million in 2019 and is projected to reach USD 3,508.0 Million by 2030, growing at a CAGR of 7.4%. Rising incidence of inflammation of nasal passage mucosa, growing prevalence of chronic asthma and paranasal sinus cases are likely to fuel the growth prospects of the chronic rhinosinusitis market over the forecast period .
The chronic myeloid leukemia (CML) treatment market is characterized by the presence of several effective therapies and ongoing research and development efforts. CML is a type of blood cancer caused by the abnormal growth of white blood cells. Targeted therapies, such as tyrosine kinase inhibitors (TKIs), have revolutionized the treatment landscape by effectively managing the disease and improving patient outcomes.
The global Chronic Myelogenous Leukaemia Treatment Market is expected to exhibit a CAGR of 6.0% during the forecast period (2023-2030) The Chronic Myelogenous Leukemia (CML) treatment market has witnessed significant advancements and growth over the years. CML is a type of blood cancer that affects the bone marrow and leads to the overproduction of abnormal white blood cells.
Chronic lymphocytic leukemia Market is estimated to reach a CAGR of 6.01% over the forecast by 2023 – 2030.The chronic lymphocytic leukemia (CLL) market is a dynamic and evolving landscape characterized by continuous research and development activities. CLL is a type of blood cancer that affects the lymphocytes, a type of white blood cell.
Chemotherapy Induced Peripheral Neuropathy Market is expected to reach US$1,174.26 million by 2030, from US$813.48 million in 2023; it is expected to register a CAGR of 5.4% from 2023 to 2030.Chemotherapy-induced peripheral neuropathy (CIPN) is a prevalent side effect that occurs as a result of treatment with antineoplastic agents.
The market for Bruton tyrosine kinase (BTK) inhibitors is anticipated to experience significant growth in the coming years. BTK is a critical component of the B cell receptor (BCR) signaling pathway, and its dysregulation has been implicated in various B-cell lymphomas, including chronic lymphocytic leukemia (CLL).
The BRAF Mutant Metastatic Melanoma Market is projected to reach a high CAGR over the forecast period 2023 - 2030.The market for BRAF mutant metastatic melanoma treatment is highly competitive and dynamic. BRAF mutations are found in a significant proportion of melanoma patients, making it a crucial target for therapy.
The global bone metastasis market size was significantly robust in 2021 and is expected to register a rapid revenue CAGR over the forecast period. Bone metastasis market revenue growth is primarily driven by the rise in cancer incidences globally.Bone metastasis refers to the spread of cancer from its original location to the bones. This process, known as metastasis, is common in various types of cancer, with breast and prostate cancer exhibiting a higher propensity for bone metastasis.
The Bile Duct Cancer Market is anticipated to reach USD 198.4 Million by 2030 at 8.60% CAGR during the forecast period 2023-2030. Cholangiocarcinoma is a kind of cancer in which epithelial cells are altered, suggesting the growth of bile duct epithelial cells. Cancer's basic aetiology is unclear.
Adenoid cystic carcinoma (ACC) is a rare form of cancer that commonly affects the salivary glands and other secretory glands. The ACC market is characterized by limited treatment options and a lack of targeted therapies due to its complex biology. However, ongoing research and development efforts are focused on identifying novel treatment strategies, including targeted therapies and immunotherapies, to improve patient outcomes.
Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics MarketInsights The Acute Lymphoid/Lymphoblastic Leukemia (ALL) Therapeutics Market is expected to experience market growth during the forecast period of 2023 to 2030. Pharmanucleusanalyzes that the market is expected to grow at a CAGR of 5.25% during the above-mentioned forecast period. Rising prevalence of acute lymphoid/lymphoblastic leukemia (ALL) is driving the market for acute lymphoid/lymphoblastic leukemia (ALL) treatments.
The global urinalysis market in terms of revenue was estimated to be worth $3.9 billion in 2023 and is poised to reach $5.7 billion by 2030, growing at a CAGR of 8.1% from 2023 to 2030. The new research study consists of an analysis of market industry trends.
The global protein A resin market in terms of revenue was estimated to be worth $1.2 billion in 2023 and is poised to reach $2.1 billion by 2030, growing at a CAGR of 9.8% from 2023 to 2030The new research study includes a market industry trend analysis. The new study report covers industry trends, price analysis, patent analysis, conference and webinar materials, important stakeholders, and market purchasing behaviour.
The global nuclear medicine market in terms of revenue was estimated to be worth $5.5 billion in 2023 and is poised to reach $9.4 billion by 2030, growing at a CAGR of 11.3% from 2023 to 2030. The new research study is an examination of market industry trends. Industry trends, price analysis, patent analysis, conference and webinar materials, important players, and market buying behaviour are all included in the new research report.
The Exophthalmos Market report, published by Pharmanucleus, provides a comprehensive analysis of the Exophthalmos condition, including its historical and forecasted epidemiology, as well as market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. The report covers current treatment practices, emerging drugs, market share of individual therapies, and the market size from 2023 to 2030, segmented by major markets.
The Ewing sarcoma market is estimated to increase at a CAGR of 6.30% between 2023 and 2030. The growing prevalence of Ewing sarcoma, improved awareness of the condition, and the discovery of novel treatment options are driving the market. Ewing sarcoma is a rare kind of soft tissue and bone cancer. It is most commonly diagnosed in children and teens, with a median age of 15 years old upon diagnosis.
It is estimated that the global cold chain market will grow to over US$278.2 billion in 2023 and reach over US$428.4 billion by the end of 2030, with GR 9.0 growth between 2023 and 2030. The globalisation of trade has boosted cross-border goods transit.
The chronic pancreatitis market is expected to grow at a CAGR of 5.70% during the forecast period of 2023 to 2030. The growth of the market is attributed to the rising prevalence of pancreatic disorders globally, increasing incidence of alcohol-induced pancreatitis, and growing demand for minimally invasive surgical procedures.
The market size for treatments for chronic lymphocytic leukaemia was estimated at USD 4.9 billion in 2023. The market for treating chronic lymphocytic leukaemia is anticipated to increase from USD 5.3 billion in 2023 to USD 8.68 billion in 2030, with a compound annual growth rate (CAGR) of 8.52% over the five-year forecast period (2023–2030).
The global chronic bronchitis market is expected to grow considerably over the projected period. The global increase in allergic reactions, as well as the growth of emerging markets, are moving this industry ahead. The increased prevalence of asthma and COPD, both of which cause severe coughing, is driving the chronic bronchitis market.
Bladder Cancer Market Size was valued at USD 5.5 Billion in 2022. The Bladder Cancer market industry is projected to grow from USD 5.8 Billion in 2023 to USD 8.2 Billion by 2030, exhibiting a compound annual growth rate (CAGR) of 4.60% during the forecast period (2023 - 2030).
Global Autoimmune Hepatitis Market, By Type (Type 1, Type 2), Treatment (Medications, Liver Transplant, Others), Diagnosis (Liver Biopsy, Blood Tests, Imaging Tests, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2030
Asthma Treatment Market is segmented By Treatment (Long-Term Control Medications,Quick-Relief Medications,Route Of Administration (Injectable,Oral,Inhaled), By Distribution Channel (Hospital Pharmacies,Retail Pharmacies & Drug Stores,Online Pharmacies), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, And Africa) – Share, Size, Outlook, And Opportunity Analysis, 2023-2030.
The worldwide antimicrobial susceptibility testing market is expected to increase at a 5.5% CAGR from 2022 to 2027, from an anticipated value of US$3.6 billion in 2022 to US$4.7 billion in 2027. The Antimicrobial Susceptibility Testing (AST) Technology Market is expanding due to factors such as rising infectious illness prevalence, increased antibiotic resistance, and favourable government measures to minimise infectious disease burden.
The Acute Pancreatitis Market Size was valued at USD 5.5 billion in 2023 and is projected to grow from USD 5.8 Billion in 2023 to USD 8.2 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.90% during the forecast period (2023 - 2030). The major market driver fueling the expansion is the increased prevalence of gastrointestinal issues.
The Acute Ocular Pain market is projected to grow significantly in the coming years. The market, which was valued at USD 195.2 Mn in 2023, is anticipated to reach USD 270.07 Mn by 2033, reflecting a compound annual growth rate (CAGR) of 3.3% during the forecast period of 2024 to 2033.
The Global Acute Ischemic Stroke (AIS) Market is estimated at USD 8,517.0 Million in 2023 and is projected to reach USD 11,185.3 Million by 2030, growing at a CAGR of 4.0% over the forecast period (2023-2030). Acute ischemic stroke (AIS) occurs when blood flow in a cerebral artery is blocked by a clot, which is a thickened mass of blood. Clots are classified as either thrombotic or embolic depending on where they form in the body.
Between 2023 and 2030, the Acute Coronary Syndrome Market is expected to grow significantly. The market will grow at a CAGR of 5.2% from 2023 to 2030, to reach USD 14,810.38 million by 2030, according to Pharmanucleus. An increase in the incidence of chronic diseases such as coronary heart disease, ischemic heart disease, and vascular disease, growing geriatric population, and diverse product offering by market players are the major drivers for the growth of the coronary syndrome market acute.
In 2023, the worldwide osteoarthritis market was valued at USD 7.40 billion and is predicted to increase at an 8.5% CAGR during the forecast period 2023-2030. Both the introduction of analgesic drugs and the development of imaging diagnostics based on radiographic characteristics are stimulating market growth. Increased expenditure on healthcare infrastructure and expanding investments in research and development (R&D) efforts to bring novel diagnostics and biomarkers are also driving the market.
The global Opioid Use Disorder (OUD) Market size was valued at USD 2.88 billion in 2023 and is projected to grow from USD 3.11 billion in 2022 to USD 5.64 billion by 2030, exhibiting a CAGR of 8.9% during the forecast period. Based on our analysis, the global market exhibited a decline of -10.1% in 2020 as compared to 2019. The global COVID-19 pandemic has been unprecedented and staggering, with opioid use disorder experiencing lower-than-anticipated demand across all regions compared to pre-pandemic levels.
Global Neuropathic Pain Market From 2023 to 2030, the worldwide neuropathic pain market is predicted to increase at a CAGR of 9.2%. The market is being pushed by the rising prevalence of chronic pain and neuropathic pain syndromes linked to a variety of illnesses. Neuropathic pain is caused by a somatosensory system lesion or illness and affects 7-10% of the general population. Multiple causes of neuropathic pain have been identified, and its prevalence is expected to rise due to an ageing global population, an increase in diabetes mellitus, and improved cancer survival following treatment.
The global CTLA-4 Therapies market is expected to reach USD 1384.4 million by 2030, at a CAGR of 7.1% during the forecast period 2022 to 2030. The modulation of cell motility and/or PI3 kinase signaling may also be other ways that CTLA-4 works. Early multiphoton microscopy investigations to observe T-cell movement in healthy lymph nodes seemed to support the
Cancer supportive care also known as palliative care is focused on relieving patients from the side effects of cancer therapies. In cancer palliative care, supportive drugs are used to lessen the side effects of cancer treatments. In many cases, cancer treatments need to be stopped or the dose needs to be lowered due to various reasons such as low blood cell counts. In such cases, supportive drugs such as CSFs enable patients to continue with cancer treatments as well as in other cases, it also allows higher doses of cancer therapies.
The bleeding disorders treatment was valued at USD 12.8 billion in 2021 and is projected to reach USD 18.6 billion by 2027, with a CAGR of 7.6% over the forecast period 2022-2027. The growth could be attributed to the return of demand to pre-pandemic levels, increasing authorization of novel & innovative medicines, extensive research, disease prevalence, and immunotherapies.
In April 2019, Creative Diagnostics developed anticoccidial drug assay products to test anticoccidial drug residues in animals. This advancement and awareness of anticoccidial drugs will impact the trend of the anticoccidial drugs market. Growing awareness of animal health and zootonic diseases is expected to increase acceptance of anticoccidial drugs. The rising carnivorous population and reliance on bovine products is expected to be a driving factor for the growth of the anticoccidial drugs market. Additionally, the increase in research and development of veterinary drugs is expected to provide growth opportunities for anticoccidial drugs.
Viral vector is the most sought-after way to transfer genes to specific cell types or tissues and manipulate them to express therapeutic genes. Currently, there are several types of viruses, such as adenovirus, adeno associated virus, baculovirus and retrovirus, which are being investigated in order to deliver the genes to required cells. This process can provide permanent as well as transient transgene expression.
Short Bowel Syndrome (SBS) is a group of problems related to poor absorption of nutrients. The main cause of SBS is surgery to remove a portion of the small intestine. This surgery can treat intestinal diseases, injuries, and birth defects. Some people are born with an abnormally short small intestine, significant damage, and poor motility, which can cause short bowel syndrome. Presently, there is no cure for SBS and the treatment is targeted toward symptoms. In a few cases, SBS can be life-threatening but usually, the disease can be managed through effective medication.
When cells in the prostate gland begin to develop unnaturally and uncontrolled, it is called prostate cancer. The prostate is a gland found solely in males that produces some of the fluid found in sperm. Surgery, radiation, hormone therapy, chemotherapy, and other treatments are available for prostate cancer. Prostate cancer therapy is determined on the stage of the disease. Prostate cancer is treated by experts such as urologists, radiation oncologists, and medical oncologists.
The market size of the global?oncolytic virus therapies in the year 2019 is valued at 84.3 million and is predicted to reach 962 million by the year 2030 at an 26.28% CAGR during the forecast period.Oncolytic viruses (OVs) are either naturally occurring or genetically modified. They only target and kill cancer cells while leaving healthy cells unharmed. This treatment, a cutting-edge approach to treating cancer patients, has had positive outcomes. Oncolytic virus therapies, which target DNA or RNA inside or outside the body, overlap biomedical research fields with similar therapeutic goals. Through genetic modification, these therapies attempt to treat an illness. The need to treat these chronic illnesses and the rising cancer incidence are the main factors driving the market growth.
Oncology Nutrition Market Forecast to 2030 - By Cancer type (Head and Neck Cancers, Stomach and Gastrointestinal Cancers, Lung Cancer, Breast Cancer, Blood Cancer, Other Cancers) and Geography.The term
The parenteral route, commonly referred to as the nasal drug delivery system, is an alternate method of medication administration.The market for nasal drug delivery technology is predicted to expand throughout the course of the forecast period as a result of factors such as rising chronic illness incidence, advanced technology, and rising demand for nasal drug delivery systems. Additionally, it is anticipated that increasing self-administration practises will present more growth opportunities for companies involved in the nasal drug delivery technology market.
Leukemia is a type of blood cancer caused by gene mutation leading to abnormal development of WBCs in the bone marrow and causes leukemia.Leukemia is also caused due to risk factors such as genetic disorders such as Down syndrome, previous cancer treatments, exposure to chemicals, smoking, and family history of leukemia or other blood disorders. The major types of leukemia are Acute Myeloid Leukemia (AML), Chronic Myelogenous Leukemia (CML), and Chronic Lymphocytic Leukemia (CLL), Acute Lymphocytic Leukemia (ALL). The majority of the AML, CML & CLL cases could be observed in adult populations, and ALL could be seen in all age groups. Leukemia treatment is based on its type, age, and ability to cope-up with the treatments.
Hemophilia is a commonly inherited group of bleeding disorders in which there is a problem with the blood clotting process. It can reflect sudden bleeding, continuous bleeding after surgery, and injuries. It contains various clotting factors that help stop bleeding, if there is any mutation in these clotting genes that mutation can inhibit the clotting protein factor, necessary to form a blood clot.
Fertility supplements contain micronutrients, which are vitamins and minerals that the human body needs in small amounts. Some people (male or female) may take these supplements to increase their chances of a healthy pregnancy. Majorly supplements are playing significant roles in women’s reproductive health and are essential for many functions, including menstruation and ovulation, thyroid function, and egg quality and maturation.
Epilepsy is a heterogeneous condition requiring individualized treatment based largely on a patient’s seizure syndrome and seizure type.The epilepsy treatment market was valued at USD 10.9 billion in 2021 and is expected to reach USD 14.6 billion by 2027, exhibiting a CAGR of 5.2% during the forecast period 2022-2027. Due to a surge in the prevalence of neurological disorders among epilepsy diseases, increases in innovative medicines & extensive research of epilepsy therapeutics around the globe, and a rise in the adoption of therapeutics by patients.
Anal cancer is generally a rare type of malignancy that affects the colon and rectum. Some of the symptoms associated with anal cancer include anal or rectum bleeding, a lump near the anus, pain around the anus, itching in the anus, discharge from the anus, changes in bowel habits, and others. It can be caused due to several risk factors such as human papillomavirus (HPV) infection, excessive smoking, and medical history of vaginal, cervical, or vulvar cancers.
A breast cyst is a noncancerous (benign), fluid-filled sac in the breast. Developed as a result of fluid accumulation inside the breast glands, this is found in women aged 20 to 50 years and it can be single or multiple. A cyst may feel like a grape or water balloon or firm.
Other than an extensive coverage of clinical and commercial drugs, our reports also provide details about pre-clinical molecules!
One of our marquee services We profile relevant start-up companies in the market.
Get access to reliable data our insights and analyses are backed by Key Opinion Leaders in the field.
Our team comprises of industry specialists and research experts from life sciences area holding degree in Medicine, Doctor of Pharmacy, M.Sc. in Pharmacy, Pharma MBAs, and Biotechnology.